Cardiology Trials

Cardiology Trials

Health EN ↓ 149 episodes

An exploration of pivotal clinical trials in cardiovascular medicine that have significantly influenced the field. This podcast aligns with our publications on the Cardiology Trial's Substack. cardiologytrials.substack.com

Be sure to visit the podcast's website and support the creator: cardiologytrials.substack.com

Author

Cardiology Trials

Category

Health

Latest episode

Oct 21, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 10M+ downloads · 4.7+ rating iOS soon

Episodes

Summary and discussion SHAM-PVI, PFA-SHAM and PVI-SHAM-AF 21.10.2026

For full review of the trials, please visit https://cardiologytrials.substack.com/ Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe

Summary and discussion of CASTLE-AF and CASTLE-HTx 13.10.2026

For full review of the trials, please visit https://cardiologytrials.substack.com/ Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe

Summary and discussion of CABANA and EARLY-AF 15.09.2026

For full review of the trials, please visit https://cardiologytrials.substack.com/ Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe

Summary and discussion of EAST-AFNET 4 28.07.2026

For full review of the trial, please visit https://cardiologytrials.substack.com/ Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe

Summary and discussion of ANDROMEDA, ATHENA and PALLAS 16.07.2026

For full review of the trials, please visit https://cardiologytrials.substack.com/ Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe

Summary and discussion of SAFE-T and RACE II 23.06.2026

For full review of the trials, please visit https://cardiologytrials.substack.com/ Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe

Summary and discussion of AFFIRM and RACE 03.06.2026

For full review of the trials, please visit https://cardiologytrials.substack.com/ Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe

Special episode (ACC 2026: CHAMPION-AF, HI-PEITHO) 06.04.2026

This is the article John referenced that discusses Watchman https://www.heartrhythmjournal.com/article/S1547-5271(17)31200-6/abstract Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe

Summary and discussion of VICTORIA and VICTOR 16.03.2026

For full review of the trials, please visit https://cardiologytrials.substack.com/ Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe

Summary and discussion of DAPA-HF and EMPEROR-Reduced 10.02.2026

For full review of the trials, please visit https://cardiologytrials.substack.com/ Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe

Special episode (AHA 2025: OCEAN, ADAPT AF-DES) 29.12.2025

Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe

Special episode (AHA 2025: VESALIUS-CV, DECAF) 08.12.2025

Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe

Summary and discussion of PARADIGM-HF and PIONEER-HF 20.11.2025

For full review of the trials, please visit https://cardiologytrials.substack.com/ Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe

Special episode (ESC 2025: AQUATIC, VICTOR) 25.09.2025

Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe

Special episode (ESC 2025: REBOOT-CNIC, BETAMI-DANBLOCK, DIGIT-HF) 09.09.2025

Discussion of landmark trials presented at the European Society of Cardiology (ESC) congress 2025 Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe

Summary and discussion of BEST and SENIORS 15.08.2025

For full review of the trials, please visit https://cardiologytrials.substack.com/ Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe

Review of the A-HeFT trial 01.07.2025

N Engl J Med 2004;351:2049-2057 Background: Endothelial dysfunction, reduced nitric oxide availability, and increased oxidative stress occur in patients with heart failure and contribute to cardiac remodeling. In the V-HeFT I trial, combining isosorbide dinitrate (a nitric oxide donor) with hydralazine (an antioxidant) improved outcomes in patients with systolic heart failure. However, its long-te...

Review of the CHARM-Alternative trial 24.06.2025

THE LANCET 2003;362:772-776 Background: Angiotensin converting enzyme inhibitors (ACEi) reduce mortality and morbidity in patients with systolic heart failure (see CONSENSUS and SOLVD trials). However, registry data showed that up to 20% of patients with systolic heart failure were not taking ACEi. One of the frequent causes for intolerance to ACEi is cough. Angiotensin converting enzyme inhibitor...

Summary and discussion of Carvedilol Prospective Randomized Cumulative Survival Study, Val-HeFT, CHARM-Added and CIBIS-II 19.06.2025

For full review of the trials, please visit https://cardiologytrials.substack.com/ Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe

Review of the CIBIS-II Trial 17.06.2025

The Lancet Volume 353, Issue 9146 p9-13 January 02, 1999 Background : Accumulating data at the time suggested functional benefits of antagonism of beta-adrenoreceptors in patients with heart failure. Multiple specific beta-blockers were being tested in trials. The CIBIS 1 trial found a trend towards 20% lower mortality in the bisoprolol (a highly cardio-selective beta-blocker) group and 30% fewer...

Review of the CHARM-Added trial 11.06.2025

THE LANCET 2003;362:767-771 Background: Angiotensin II which plays a role in ventricular remodeling and progression of heart failure can be produced by pathways independent of angiotensin convening enzyme. Preliminary studies showed that the combination of angiotensin II blockers with angiotensin-converting enzyme inhibitors (ACEi) improves hemodynamics and reduces ventricular remodeling. Cardiolo...

Review of the Val-HeFT trial 06.06.2025

N Engl J Med 2001;345:1667-1675 Background: Angiotensin II is a peptide hormone that is part of the renin–angiotensin–aldosterone system (RAAS). Angiotensin II is a potent vasoconstrictor and growth-stimulating hormone. Data suggested that it plays a role in ventricular remodeling and progression of heart failure. Although treatment with angiotensin-converting enzyme inhibitors (ACEi) reduce angio...

Review of the Carvedilol Prospective Randomized Cumulative Survival Study 04.06.2025

N Engl J Med 2001;344:1651-1658 Background: The MERIT-HF trial demonstrated the efficacy of the selective beta blocker metoprolol CR/XL for well selected patients with chronic systolic heart failure who were on optimal therapy with an ACEi and diuretic. The trial randomized nearly 4,000 patients and was stopped early due to the benefit of the drug on all-cause mortality but it also reduced major m...

Summary and discussion of U.S. Carvedilol Heart Failure, DIG, RALES, MERIT-HF, and ATLAS 30.05.2025

For full review of the trials, please visit https://cardiologytrials.substack.com/ Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe

Review of the ATLAS trial 27.05.2025

Circulation 1999;100:2312-2318 Background: The CONSENSUS and SOLVD trials established the effectiveness of angiotensin converting enzyme inhibitors (ACEi) in reducing mortality and morbidity in patients with systolic heart failure. Both trials used enalapril with a target dose of 20mg twice a day (max dose) in the CONSENSUS trial and 10mg twice a day (medium dose) in the SOLVD trials. In real-worl...

Listen to the Cardiology Trials podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.